Literature DB >> 12161030

Substance P receptor expression on lymphocytes is associated with the immune response to respiratory syncytial virus infection.

Ralph A Tripp1, Albert Barskey, Laura Goss, Larry J Anderson.   

Abstract

The kinetics and magnitude of SP receptor expression was determined for bronchoalveolar leukocyte cell subsets from BALB/c mice in the primary immune response to respiratory syncytial virus (RSV) and human parainfluenza virus-3 (PIV3) infection, and in the secondary immune response to RSV and PIV3 challenge. In both the primary and secondary responses to infection, expression of substance P (SP) receptors was markedly increased by infection, especially for T lymphocytes, compared to B220+, CD11b+ and CD14+ cells. CD4+ T lymphocytes predominantly expressed SP receptors in the secondary response. These results suggest that SP receptor expression may be important in the development of primary and secondary immune responses to respiratory virus infections.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12161030     DOI: 10.1016/s0165-5728(02)00169-8

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  15 in total

1.  Measurement of plasma-derived substance P: biological, methodological, and statistical considerations.

Authors:  Donald E Campbell; Nancy Raftery; Richard Tustin; Nancy B Tustin; Michelle L Desilvio; Avital Cnaan; Pyone Pyone Aye; Andrew A Lackner; Steven D Douglas
Journal:  Clin Vaccine Immunol       Date:  2006-09-13

2.  Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P.

Authors:  Lia M Haynes; Les P Jones; Albert Barskey; Larry J Anderson; Ralph A Tripp
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

3.  A respiratory syncytial virus (RSV) anti-G protein F(ab')2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice.

Authors:  Seyhan Boyoglu-Barnum; Kelsey A Gaston; Sean O Todd; Cemil Boyoglu; Tatiana Chirkova; Thomas R Barnum; Patricia Jorquera; Lia M Haynes; Ralph A Tripp; Martin L Moore; Larry J Anderson
Journal:  J Virol       Date:  2013-07-24       Impact factor: 5.103

4.  Neuroimmune link in the mucosa of chronic gastritis with Helicobacter pylori infection.

Authors:  G Sipos; K Altdorfer; E Pongor; L P Chen; E Fehér
Journal:  Dig Dis Sci       Date:  2006-10       Impact factor: 3.199

5.  RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response.

Authors:  Wenliang Zhang; Ralph A Tripp
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

Review 6.  Understanding the mechanisms of viral induced asthma: new therapeutic directions.

Authors:  Nicole G Hansbro; Jay C Horvat; Peter A Wark; Philip M Hansbro
Journal:  Pharmacol Ther       Date:  2008-01-29       Impact factor: 12.310

7.  Novel method for determination of substance P levels in unextracted human plasma by using acidification.

Authors:  Donald E Campbell; Paula Bruckner; Nancy B Tustin; Richard Tustin; Steven D Douglas
Journal:  Clin Vaccine Immunol       Date:  2009-02-04

8.  PCR based bronchoscopic detection of common respiratory pathogens in chronic cough: a case control study.

Authors:  Peter W West; Angela Kelsall; Samantha Decalmer; Winifred Dove; Paul W Bishop; James P Stewart; Ashley A Woodcock; Jaclyn A Smith
Journal:  Cough       Date:  2012-09-14

9.  Bioinformatic screening of autoimmune disease genes and protein structure prediction with FAMS for drug discovery.

Authors:  Shigeharu Ishida; Hideaki Umeyama; Mitsuo Iwadate; Y-H Taguchi
Journal:  Protein Pept Lett       Date:  2014       Impact factor: 1.890

10.  Induction of tachykinin production in airway epithelia in response to viral infection.

Authors:  James P Stewart; Anja Kipar; Helen Cox; Catherine Payne; Sylvia Vasiliou; John P Quinn
Journal:  PLoS One       Date:  2008-03-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.